CND Life Sciences Secures $13.5 Million in Series A Funding to Advance Parkinson’s Diagnostic Technology
CND Life Sciences, a biotechnology firm revolutionizing neurodegenerative disease diagnostics, has successfully raised $13.5 million in its Series A funding round, including $8.6 million from its recent Series A3 tranche. This funding milestone will further accelerate the adoption of CND’s flagship innovation—the Syn-One Test®, a skin biopsy-based diagnostic tool designed to detect abnormal alpha-synuclein, a … Read more